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ABSTRACT

Background and Purpose: Charcot-Marie-Tooth (CMT) is the most common inherited

peripheral neuropathy and affects both motor and sensory nerves. Clinical presentation is
similar among all types and results in distal muscle atrophy and weakness, diminished
sensation and proprioception, and balance and gait disturbances. Pes cavus is a prominent
feature. Although gene therapy and neurotrophic growth factors show promise as
treatment, physical therapy remains the most viable option at this time. The purpose of
this case report is to determine the effect that physical therapy may have on both physical
and psychological outcomes related to CMT.
Case Description: Patient was a 51-year-old-female presenting to physical therapy with a

diagnosis of CMT. She presented with lower extremity pain, muscle weakness and
atrophy, diminished or absent sensation and proprioception, gait deviations, and
increased ditftculty navigating stairs. Her main goal was to remain an independent
ambulator for as long as possible. Her pain was managed with gabapentin. She did not
report any involvement with her upper extremities.
Intervention: A resistance training program focusing on balance, stepping activities and

lower extremity strength was initiated carried out as an outpatient and home exercise
program. Massage and soft tissue work was applied to the legs and feet.
Outcome: The patient was seen for 18 total visits. At discharge, her balance, tandem

stance, lower extremity strength all improved. She reported feeling more confident with

Vll

ambulation and was less anxious about the disease process. A referral to a podiatrist was
given for custom orthotics.

Discussion: Patient's with CMT often report difficulty with mobility and ambulation,
specific activity impairments, fatigue, and emotional distress. In spite of this, they are
often not referred to or attend physical therapy as the perceived benefit is small.
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CHAPTER I
BACKGROUND AND PURPOSE

Charcot-Marie-Tooth (CMT) is the most commonly inherited peripheral
neuropathy. It is named after the three physicians who first described it: Jean-Martin
Charcot, Pierre Marie, and Howard Henry Tooth. CMT is also known as peroneal
muscular atrophy (PMA) or hereditary motor sensory neuropathy (HMSN). CMT is
found world-wide among all races and ethnic groups and affects an estimated 40
individuals in every 100,000. 1 There are many forms ofCMT disease, including CMTl,
CMT2, CMT3, CMT4 and CMTX. For an overview of the genotypes, phenotypes and
clinical presentations, the reader is referred to the work of El-Abassi et al 2 CMTl
accounts for more than two-thirds of all cases. CMT is not contagious and not attributable
to an environmental cause.
Some types of CMT cause damage to the myelin sheaths (CMTl: typically
inherited in an autosomal dominant pattern; CMT4: inherited in an autosomal recessive
pattern) while some types damage the nerve axons themselves (CMT2: inherited in an
autosomal dominant pattern).2 Both the sensory and/or the motor fibers can be affected
causing weakness, numbness, and diminished or complete loss of sensation most
commonly in the distal extremities but any nerve of the body can become affected. In
most cases, it is a slowly progressing peripheral neuropathy. Any signs of a quickly
deteriorating neurological process should prompt an immediate re-evaluation as this can

1

indicate a much more serious or life threatening disease process. CMT in itself is
generally not considered life threatening but rare variants of the disease can affect the
autonomic respiratory and cardiac nerve fibers, compromising heart and lung function?
Brain function is normally spared.
Individuals with CMTl or CMT2 usually become symptomatic between age 5
and 25 years with age of onset ranging from infancy to the fourth and subsequent
decades. Clinical severity is variable, ranging from extremely mild disease that goes
unrecognized by the affected individual and physician to considerable weakness and
disability.l Although there are many different genetic causes of CMT, all types tend to
have remarkably similar symptoms. Pes cavus is usually present, although pes planus can
also be typical. As the disease progresses, structural deformities take place depending on
which nerves and corresponding muscles are affected, causing abnormal forces across the
joint. Typically, the distal nerves ofthe feet and hands are affected first.2 Proximal
muscle weakness is rarely present except in the most severely affected patients. Although
it is not fully understood why proximal muscles are typically spared, the mutations in
many different genes lead to dysfunction of many proteins eventually leading to axonal
degeneration that is length-dependent. 4 • 5 Muscle atrophy of the lower legs and intrinsic
foot and hand musculature is also common. Muscle atrophy in the lower leg can lead to
what has been described as an "inverted champagne bottle" appearance. Neuropathic pain
such as numbness and tingling can range from annoying pain to more debilitating pain
that can affect activities of daily living and typically requires medication to manage
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CMT is typically diagnosed by a neurologist through a thorough neurological
evaluation, including a complete family history, physical exam, and nerve conduction
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tests. If appropriate, genetic testing can confirm the diagnosis. For a diagnosis of CMTl,
a reduced ulnar nerve conduction velocity of less than 38 mlsec is required. 1 In
comparison, normal ulnar nerve conduction velocities average 52.4m1s for adults aged
50-59 years 01d. 7 Typically, the first signs may include leg weakness, unexplained
frequent tripping, and/or falling. A physical exam may show (l) foot drop, (2) reduced or
absent deep tendon reflexes, (3) atrophy in the feet and lower leg resulting in an inverted
champagne bottle appearance (4) high arches, (5) hammer toes, (6) problems with
balance, and (7) gait disturbances. 8 Patients may lose feeling in their hands and/or feet,
putting them at risk for blisters, burns, and sores.
There is no known cure for CMT. Large randomized controlled studies have
examined the efficacy of ascorbic acid, a vital component for the regeneration of
nerves. 9,10 Rat models have shown promise, but these studies have not shown any
beneficial effects for humans with CMT. Other investigational therapies underway
include identifYing neurotrophic growth factors, specifically neurotrophin 3 (NT3), which
expressed by Schwann cells to promote myelination. 11 Many gene therapy investigations
are also underway. 12 Certain medications, such as vinca alkaloids (vincristine) pose a
definite risk and can exacerbate CMT symptoms. Gabapentin is believed to have a
negligible or doubtful risk of exacerbating CMT symptoms. 13
Moderate resistance training has been shown to be effective at reducing fatigue
and increasing quality of life in people with CMT. Although an exact resistance has not
been established, it is generally thought that too high of a resistance performed too often
can be deleterious to people with CMT and cause overuse weakness. 14 However, more
recent evidence refutes this theory.15,16 A home-based strength training program for the
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knee extensors and flexors and elbow extensors and flexors, progressively increasing
resistance through 4 phases over 12 weeks, resulted in improved strength and activities of
daily living and was equally effective for men and women with CMT.17 The additional
ingestion of creatine has not been found to be beneficial.

18

A 12-week exercise program

of moderate resistance (30% of maximum isometric force) resulted in strength gains
ranging from 4% to 20% without any notable harmful effects. 19 However, in the same
population, a 12-week high resistance exercise program (ie, training at the maximum
weight a subject could lift 12 times) showed no added beneficial effect compared with the
moderate-resistance program and evidence showed overwork weakness in some ofthe
subjects. Lindeman et al show that progressive resistance training can increase muscle
force production as measured through surface EMG?O A 12-week walking program
consisting of 30 minutes per day, 3 to 4 times per week reduced both submaximal heart
rate and blood pressure and was well tolerated by all individuals?l Twenty-four weeks of
interval training exercise cycling has also shown to increase cardiorespiratory function in
people with CMT.22 Physical therapy, occupational therapy, and moderate physical
activity continue to be the mainstay of treatment and can be beneficial in reducing
fatigue, while increasing endurance and strength.
The purpose of this case report is to describe the anatomical and physiological
effects CMT has on the body, patient presentation at initial evaluation, the effects of a
strength and conditioning program, and describe the patient's functional status and her
perception of the disease process following care.

4

CHAPTER II
CASE DESCRIPTION
Examination

History
This patient was a 51-year-old female presenting to physical therapy with a
diagnosis of Charcot-Marie-Tooth. She was diagnosed in early 2005 with the disorder but
was unsure of the type. The patient had a family history of CMT as both her mother and
grandmother had the disease. At the time of diagnosis, she was independent in all
activities but did report stubbing her toes often and falling at various times. Before she
was diagnosed, she attributed these falls to clumsiness. She had recently started having
more trouble negotiating stairs, especially if she was holding anything with her arms such
as laundry and now required use of handrails. She also stated that she had trouble
descending hills or sidewalks but does not have as much trouble ascending them. She
reports feeling stronger leading with her left leg up stairs.
After she was diagnosed in 2005, she was told that not much could be done for
her. She was referred to a specialist at a local University hospital where she was again
referred to an orthopedic surgeon for surgery to correct her foot deformity. She refused
surgery at that time but was prescribed gabapentin to reduce the nerve pain in her feet.
Since then, she has seen various healthcare practitioners who have tried various
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treatments, including acupuncture and massage, without much success at relieving pain
and/or improving function.
She currently works an office job and sits at a desk for upwards of ten hours per
day taking only occasional standing breaks. She attributed the prolonged sitting to fear of
walking and possibly tripping or falling in the workplace. She lives in a 2-two story
house with her husband and has two children, who are both in college. She reported being
previously independent in all activities of daily living (ADLs) but currently has trouble
negotiating stairs and hills. She was eventually referred to physical therapy with orders to
evaluate and design an appropriate strength and conditioning program. She stated that she
is knowledgeable about CMT and its course but was frustrated that she has been
"bounced" around from practitioner to practitioner without anyone really trying anything.
She was also anxious about the course of the disease due to her mother and grandmother
ending up in wheelchairs from CMT. Because of this, she was highly motivated to try
physical therapy. She denied any history of alcohol or tobacco use
Pain
Her pain is managed by gabapentin which she takes three times a day: in the
morning, midafternoon, and before bed. The mechanism by which gabapentin exerts its
analgesic action is unknown but is currently prescribed for neuropathic pain. Gabapentin
is a gamma-aminobutyric acid analog (GABA), which is the chief inhibitory
neurotransmitter in the human nervous system. However, gabapentin is not appreciably
metabolized in humans but rather acts to increase GABA synthesis thus inhibiting the
nervous system and signal transmission leading to reduced pain sensation.23 Gabapentin
typically keeps her pain manageable, which she rated at 311 0 with 0 being no pain and 10
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being the worst imaginable pain. Her pain never decreases to 0 and will get as bad as a
711 0 if she misses a gabapentin dosage. Due to the foot and leg pain, she often has
difficulty falling asleep at night. She has found that quickly performing sidelying hip
abduction at very high repetitions (upwards of 125 on left, often not as many on the right
as that side does not feel as strong) fatigues her and she will fall asleep.
Objective tests and measures

Observation revealed genu valgum, genu recurvatum, pronated feet (left greater
than the right), slight atrophy throughout bilateral leg musculature, most notably in the
fibularis and triceps surae. She does not currently wear any braces or ankle-foot orthoses
(AFO) but does wear over-the-counter foot orthotics. At this time, she does not believe
she needs a custom foot orthotic or an AFO. The bony prominences were readily seen
throughout her feet bilaterally due to the atrophy of her lower leg and intrinsic foot
muscle. No skin breakdown or pressure sores are readily apparent on her feet and ankles.
An observational gait analysis revealed limited heel strike and flat foot which
slaps down (possibly because she lacks sensation andlor proprioception in her feet and
has general DF weakness) at initial contact. During mid-stance, her adductors pull her
into a slight "scissoring-type" gait. She displayed minimal push-off during late stance
phase which would cause her knee to hyperextend and lock out. During swing phase, she
displayed a slight circumduction swing through to increase her foot clearance. She does
not use an assistive device.
Her lower extremity range of motion was within norrnallimits bilaterally except
for reduced dorsiflexion bilaterally. Joint play assessment revealed bilateral
hypermobility throughout her feet. Her lower extremity strength graded 3+/5 to 4/5
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bilaterally throughout except for left hip abduction graded 5-15. Pin prick and light touch
(gently sweeping the hands over the legs and feet) sensation were diminished or absent
throughout bilateral legs and feet. She stated that she has been told that she has over 90%
sensory loss in her feet and that she had mild hypersensitivities to hot and cold
temperatures. Patellar and Achilles reflexes were diminished bilaterally. Single-leg stance
required continuous fingertip touch for balance. She was unable to perform a full squat
due to her hip joints internally rotating and adducting causing genu valgum. Upper
extremity testing was deferred due to no involvement at this time. A McGill pain
questionnaire was filled out but neither a functional scale such as a SF-36 nor a more
specific scale such as the CMT neuropathy score was administered.

Evaluation
The patient is a 51 year old female presenting to physical therapy with a diagnosis
of CMT. Her chief complaint was anxiousness related to the disease process and
potentially ending up in a wheelchair which happened to both her mother and
grandmother. She remains independent in all activities with the exception of navigating
stairs which she requires the use of a hand rail. Because of this, she is unable to carry
anything (ie, laundry) up and down the stairs in her house. Her pain remains at a 2 to 3
out of 10 and is managed by gabapentin, which she takes daily. An observational gait
analysis revealed slight foot slap and knee hyperextension at initial contact, reduced
push-off during late stance, and a circumduction swing through gait to compensate for
her slight foot drop. Single-leg balance requires continuous finger-tip touch assistance.
Sensation is diminished or absent throughout her legs bilaterally and she displays mild
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hypersensitivities to hot and cold. Muscle atrophy is present throughout her legs and feet.
Her upper extremities remain unaffected at this point.

PT Diagnosis
According to the Guide to Physical Therapist practice, the patient was classified
under the preferred practice pattern 5F: Impaired Peripheral Nerve Integrity and Muscle
Performance Associated with Peripheral Nerve Injury. An ICD-9-CM code of 356.1:
Peroneal muscular atrophy was used to classify the disease.

Prognosis
Prognosis was judged to be fair to good due to the progressive nature of the
disease and lack of viable treatment options. However, due to high motivation levels and
having overall good health, and the fact that she was able to maintain an almost normal
grade (5-/5) in side-lying hip abduction by performing high repetitions almost nightly to
aid her in falling asleep, it was hypothesized that with a well-rounded strength and
conditioning program she may be able to offset some of the negative effects, such as
deconditioning due to reduced physical activity, of the disease process.
The primary long term goal for the patient was to remain and independent
ambulator for as long as possible and to potentially offset the de conditioning associated
with reduced activity levels due to CMT. Other long term goals included decreased pain
levels if she happened to miss a gabapentin dosage, maintaining current manual muscle
test scores or possibly increasing them to 4/5 throughout bilateral lower extremity,
improved stepping and gait performance to better negotiate stairs, and reduce the risk of
future falls. Short term goals included improving her single leg balance with eyes open to
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20 seconds bilaterally and being 100% adherent with her home exercise program. These
goals were deemed to be realistic and attainable by both the patient and therapist.
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CHAPTER III
INTERVENTION
A comprehensive resistance training program was developed and was carried out
in and outpatient clinic and as a home exercise program. The main focus of the program
was on the lower extremity although upper extremity exercises were also incorporated.
An emphasis was placed on balance and stepping activities to help prevent future falls
and negotiation of stairs and hills. Manual therapy in the form of soft tissue massage was
performed to her lower legs and feet as the patient reported relief with this technique.
Due to her lack of sensation to her feet and legs, she was encouraged to check them daily
for skin breakdown. The following table contains a list of interventions and exercises
performed.
Table 1. Interventions and Exercises Performed

Lower Extremity
-Manual therapy including soft tissue
massage to feet and lower leg
-Doorway squats
-Single leg balance/tandem walking
-Heel/toe raises
-Vigor Gym Squats
-Multi-planar lunges
-Step-ups (forward and lateral)
-Walking lunges

Upper Extremity
-Standing rows
-Wall pushups
-Lat pUlldown
-Pulley pulldown CUE and core)

A typical treatment session would include 10 to 15 minutes of soft tissue work to
her feet and lower legs and 45 minutes of resistance training exercise. She would perform
6 to 8 exercises in any given session and exercises would be alternated from session to
11

session. Progressions included higher steps, more repetitions, quicker repetitions, and
removal of any external assistance, ie, fingertip touch during SL stance.
Although stationary cycling would be an appropriate exercise type, she did not
have one at home and was not a member of a health club so that she could have access to
one. Outdoor cycling was not appropriate for her due to balance deficits and that a few
years ago, she noticed that her right foot would slip off of the pedal at random times. She
was not sure why this would happen but the therapist speculated that it may be due to
lack of proprioception in her feet. Treadmills were also deemed inappropriate due to her
foot drop, lack of proprioception and increased risk of a fall potentially leading to injury.
Swimming was suggested but due to time constraints and lack of proximity to a pool she
stated that swimming was not a realistic option at this point.
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CHAPTER IV
OUTCOMES
The patient was seen for eighteen total visits over a twenty week span at which
point a mutual decision was made to discharge her. A referral to a podiatrist was given
should she decide to have custom orthotics made. Her home exercise program was
progressed each session by increasing the number of reps, weight, sets, or amount of
support for balance. She reported 100% adherence with no increases in fatigue or
soreness and stated that she would often perform 2-3 times as many repetitions as the
program called for. Lower extremity manual muscle testing increased from 3+/5 to 415
bilaterally throughout. Single leg balance for thirty seconds improved from continuous to
intermittent fingertip touch. Tandem stance improved from requiring intermittent
fingertip touch to independent tandem stance with external perturbations. She reported
feeling more confident with ambulation and would take more walking breaks during
work. She continued to be diligent with foot checks for skin breakdown that could result
in a neuropathic ulcer. No apparent skin breakdown was evident at any point during
therapy. She was versed in proper footwear and areas that are more prone to skin
breakdown such as bony prominences and metatarsal heads. Overall, she stated that her
pain may be somewhat better but will still increase to a 6-711 0 if she misses a gabapentin
dosage. At her fourth session of therapy, she did report falling while shopping for
groceries but said this was due to her being in a rush.
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CHAPTER V
DISCUSSION
CMT is a slowly progressing peripheral neuropathy that affects both sensory and
motor nerves in a variety of ways (demyelination, axonal destruction, etc) depending on
the genotype. Patients frequently report difficulty with mobility and ambulation, specific
activity impairments, and emotional distress closely followed by pain, numbness and
fatigue 24 Health-related quality oflife (HRQoL) in CMT was strongly predicted by lower
limb weakness and to a lesser extent by leg cramps, suggesting clinical trials targeting
weakness and cramps may improve HRQoL in patients with CMT. 25 A survey by Calvert
et al showed that people with rare neurological disorders, such as CMT, are less likely to
seek out healthcare and/or social services that could have a positive impact on the
HRQoL and may reflect a lack of coordination of care. 26 A lack of effective interventions
may be contributing to this and as such, healthcare practitioners that encounter these
types of patients are less likely to refer them for treatment such as physical or
occupational therapy. Patients often perceive physical and mental benefits from
rehabilitation, but also perceive that the best rehabilitation program is not being
performed. On top of that, familiar and/or caregivers do not necessarily think the
rehabilitation is effective which may be due to the small benefits generally achieved by
the patient and not readily appreciated by the family or caregiver. 27 While the research is
somewhat conflicting and sparse as to the effectiveness of physical therapy at improving
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function in people with CMT, it is currently the best available option until other therapies
such as gene or neurotrophic factors (ie, NT3) become viable.
Surgery is often offered to patients with CMT to correct structural deformities of
their feet to increase gait efficiency. At this point, she has not considered having surgery
as she remains an independent ambulator. She was, however, encouraged to try a custom
orthotic as opposed to the over-the-counter orthotics she currently used. Due to the
flexible nature of her pes planus, the therapist speculated that a custom orthotic could
help to improve gait efficiency and even possibly reduce the risk for future falls.

Reflective Practice

One of the main reasons for using CMT for this case report was the lack of
familiarity with not only CMT, but also the interventions currently used to treat it. On an
interesting and encouraging note, because she was able to maintain 5-/5 manual muscle
grade in her left hip abduction (possibly from performing high repetition side-lying hip
abduction nightly), the therapist speculated that early intervention for patients with CMT
may offset the progression of the disease and potentially allow for strength gains to be
made. However, due to the progressive nature of the disease and the degeneration of
myelin or the axons themselves, any benefits or improvements are generally small and
probably attributable to the reversal of general deconditioning rather than direct
improvements to the nerves and muscles themselves.
Other things that could have been addressed were upper extremity testing such as
grip strength, sensation, reflexes and proprioception. This could have allowed for some
objective tests and measures to quantify any progression of the disease in the upper
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extremity. Although the clinic did not have a handheld dynamometer to assess muscle
strength, this could have objectively quantified any potential strength gains rather than
subjective manual muscle scores. Although a McGill pain questionnaire was filled out, no
specific functional scale, such as the CMT neuropathy scale or SF -36 was administered,
it could have been beneficial to fill one out to asses her current quality of life, to have a
better understanding of how she perceives the disease process is affecting her life, and to
detect any changes in functions that therapy may have had.
Sometimes what gets lost in practice is the fact that we get so caught up in seeing
or making improvements in everyone we treat, we often forget that when we are dealing
with slowly progressing diseases such as CMT, the fact that they are improving as
opposed to declining should be viewed in a more positive light. While we do not
currently have the ability to restore myelin or regenerate axons in patients that have a
slowly progressing peripheral neuropathy, physical activity may benefit people with
CMT. In spite of the lack of evidence for physical therapy, we as practitioners should be
even more diligent as to how we help and treat these patients. They should not be
dismissed or tossed from one practitioner to another because there is no cure. At the very
least, referrals should be given to the appropriate healthcare professionals as these
patients can typically benefit from increased quality oflife such as sleeping better,
reduced pain, coping strategies and possibly increased strength and endurance. In
addition to that, if a diagnosis is made early and referral to physical or occupational
therapy is made, perhaps some of the deconditioning from inactivity can be staved off
and muscle strength can be maintained longer or, at the very least, the deterioration can
be minimized.
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Table 2. Summary oflntervention Studies
Significant
Study
Wright, NC
et al (1996)21

Mhandi, LE
et al (2007)22

Lindeman, E
et al (1999)20

Subjects
N~8, 4 men, 4
women, mean age
36.6 y/o ; slowly
progressing NMD
N~8

Intervention

Measurements

outcomes

12- week walking
15-30min,34x!week
50-60%HRR

Resting, submax and peak

-SubmaxHR ~
-Submax SBP ~

(all men);
CMTl: mean age
32y/o
CMT2: mean age 34
y/o

24-week cycling
program

N~33

24 week
progressive RT

(myotonic
dystrophy)
N~29 (CMT)

HR
SBP andDBP
02 uptake

-Well tolerated

peak power output
V02max, peale power,

-V02max t

knee ext/flex strength,
ascending/descending 9
stairs, walking

-Peak power i
-Stairs time t

Isometric knee extension
force production measured
via surface EMG
(maximum volunatary

-50m walk time 1
-60m walk time 1
-MVCknee
extension force

i

21%

contraction (MVC)
Chetlin, RD
et al (2004),7

N~20, II women, 9
men; mean age
45y/o

12 weeks
progressive
strength training,
3d/wk,

Timed ADLs, isometric

DE and LE strength, body
composition

-Chair rise, supine
rise, stair climb
improved. Women achieved
80%nOlmal
strength norms in
6/8 measurements

of MVIS
-Well tolerated

Chetlln, RD
et all (2004)18

N~20, II women, 9
men; mean age
45y/o

Progressive
strength training
3d/wk, 12 weeks
with or without
creatine
supplementation

,

Muscle fiber type and size,
strength, and ADLs

-Type lIb fiber
size i
-Lift and reach,
chair rise, supine
rise and stair
improved
significantly
-No benefit from
creatine

N1vID - Neuromuscular disease; HRR - heart rate reserve; MVIS = maximum voluntary isometric
strength; MVC ~ Maximum voluntary contraction; LE ~ Lower extremity; UE ~ Upper Extremity; ADL ~
Activity of daily living
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